EVNIN LUKE sold $64K of HOWL (indirect holdings)

EVNIN LUKE sold 139,803 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at an average of $0.46 ($0.42–$0.47) across 3 trades over 2026-06-01 to 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · EVNIN LUKE
Published Jun 3, 2026, 10:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HOWL
Bearish
medium confidence
Mentioned
$HOWL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HOWLBearishLow
01

Why it matters

A director's modest share sale under a 10b5‑1 plan provides limited new information for traders.

02

Market read

The filing is a routine insider transaction with low trading relevance.

03

What to watch

Potential upcoming clinical data could offset any negative perception from the sale.

Relevance 2/10Novelty 2/10Timing: today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$HOWLBearishMedium confidence
Context

Director EVNIN LUKE sold ~64K USD of shares via a 10b5-1 plan, reducing his stake to 482,776 shares.

Expected impact

likely slight pressure as the market prices in the insider sell.

Evidence & confidence

Sale amount under $100K and executed under a pre‑arranged plan; limited material impact on share price.

Market effects

Minimal effect on the biotech sector; insider sales are routine.

No regional impact.

None.

Counterpoint

The sale could be purely liquidity‑driven; investors may ignore it.

Key entities

  • Werewolf Therapeutics, Inc.

    Biotech company listed on NASDAQ under ticker HOWL.

  • EVNIN LUKE

    Director of Werewolf Therapeutics who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HOWLMedAI 8/10

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou